Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novo Nordisk A/S : – Share repurchase programme

10/26/2020 | 07:48am EST

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 26 October 2020– On 6 August 2020, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 17 billion to be executed during a 12-month period beginning 5 February 2020.

Under the programme initiated 6 August 2020, Novo Nordisk will repurchase B shares for an amount up to DKK 2.8 billion in the period from 6 August 2020 to 28 October 2020.

Since the announcement as of 19 October 2020, the following transactions have been made:

 Number of
B shares
purchase price
value, DKK
Accumulated, last announcement5,699,491 2,438,059,929
19 October 2020100,000452.2045,220,380
20 October 2020100,000453.7345,373,460
21 October 2020100,000448.5944,858,712
22 October 2020100,000446.7844,677,753
23 October 2020100,000446.2944,629,040
Accumulated under the programme6,199,491 2,662,819,274

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 26,247,394 B shares of DKK 0.20 as treasury shares, corresponding to 1.1% of the share capital. The total amount of A and B shares in the company is 2,350,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 17 billion during a 12-month period beginning 5 February 2020. As of 23 October 2020, Novo Nordisk has since 5 February 2020 repurchased a total of 26,258,670 B shares at an average share price of DKK 427.04 per B share equal to a transaction value of DKK 11,213,607,006.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 43,100 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.

Further information

Anne Margrethe Hauge+45 4442 3450amhg@novonordisk.com
Ken Inchausti (US)+1 609 240 9429kiau@novonordisk.com
Daniel Muusmann Bohsen+45 3075 2175dabo@novonordisk.com
Valdemar Borum Svarrer+45 3079 0301jvls@novonordisk.com
Ann Søndermølle Rendbæk+45 3075 2253arnd@novonordisk.com
Mark Joseph Root+45 3079 4211mjhr@novonordisk.com
Kristoffer Due Berg (US)+1 609 235 2989krdb@novonordisk.com

Company announcement no. 61 / 2020


  • CA201026_Safe_Harbour

© OMX, source OMX

All news about NOVO NORDISK A/S
11/23NOVO NORDISK A/S : – Share repurchase programme
11/20India's Gland Pharma jumps 23% in market debut
11/18NOVO NORDISK A/S : - Once-weekly semaglutide 2.0 mg demonstrates superior reduct..
11/18NOVO NORDISK A/S : Experts Urge Govt to Subsidise Cost of Diabetes Management, T..
11/17NOVO NORDISK A/S : Once-weekly semaglutide 2.0 mg demonstrates superior reductio..
11/16GILEAD SCIENCES : and Novo Nordisk Present New Data from Proof-of-Concept Trial ..
11/14NOVO NORDISK A/S : Diabetes - Novo Nordisk to Offer Free Insulin to Children in ..
11/12NOVO NORDISK A/S : set to acquire Emisphere for $1.8 billion
11/09NOVO NORDISK A/S : to acquire Emisphere Technologies and obtain ownership of the..
11/09NOVO NORDISK : UBS reiterates its Neutral rating
More news
Sales 2020 127 B 20 440 M 20 440 M
Net income 2020 42 174 M 6 766 M 6 766 M
Net cash 2020 8 472 M 1 359 M 1 359 M
P/E ratio 2020 22,9x
Yield 2020 2,17%
Capitalization 960 B 154 B 154 B
EV / Sales 2020 7,47x
EV / Sales 2021 7,01x
Nbr of Employees 44 326
Free-Float 75,1%
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 27
Average target price 439,69 DKK
Last Close Price 414,75 DKK
Spread / Highest target 31,4%
Spread / Average Target 6,01%
Spread / Lowest Target -30,1%
EPS Revisions
Lars Fruergaard Jørgensen President & Chief Executive Officer
Helge Lund Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S7.27%153 607
JOHNSON & JOHNSON-1.50%378 244
ROCHE HOLDING AG-3.47%285 939
NOVARTIS AG-11.58%203 854
PFIZER INC.-1.59%203 048
MERCK & CO., INC.-11.97%202 555